Previous studies have shown that fulvestrant, a pure antiestrogen and a potent estrogen receptor (ER) antagonist, exhibited a distinct anti-cancer effect on LUAD78, 79, yet the precise mechanism underlying this effect remains elusive. Here, ESR1 is linked to cancer.